RKRyota Kikuchi

Ryota Kikuchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryota Kikuchi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interindividual variability in hepatic hydrolytic enzymes: Effects of age, sex, and race on the abundance of drug-metabolizing hydrolases

    by Dilip Kumar Singh, Deepak Ahire, Scott Heyward, Robert S. Jones, S. Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard P. Murray, Bill J. Smith, et al.

  • Open Access

    Optimization of Bottom‐Up PBPK Model Development in SIMCYP via Retrospective Analysis of Clinical Human PK Data

    by Julia A. Schulz Pauly, Alix F. Leblanc, Ekram A. Chowdhury, Yuli Qian, Leyla Rezaei, Christine M. Lee, Mohamed Badawi, Ryota Kikuchi

    Physiologically‐based pharmacokinetic (PBPK) modeling has become a major tool in drug discovery and development. Here, we describe the bottom‐up PBPK modeling approaches employed at AbbVie using Simcyp Simulator and evaluate the impact of three system parameters, GI physiology, P‐gp Relative Expression Factor (REF), and recombinant CYP enzyme (rCYP) intersystem extrapolation factor (ISEF), independently and in combination, on PBPK prediction performance through retrospective analysis of 8 clinical assets. Overall, the application of New GI physiology resulted in a considerable improvement in the prediction of oral absorption for most compounds compared to the Original GI physiology (C max : 76% vs. 43% within 3‐fold) when using the default P‐gp REF (1.5) and adjusted ISEF. Decreasing P‐gp REF to 0.5 resulted in additional improvement in the predictions of C max for P‐gp substrates (86% within 3‐fold). The observed plasma exposure‐time profiles and AUC INF are better predicted using the default rCYP ISEF values instead of individually adjusted values (48% vs. 43% within 3‐fold) when using the Original GI and default P‐gp REF (1.5). The combination of optimized parameters (New GI physiology, P‐gp REF of 0.5 and rCYP default ISEF) predicted the plasma exposures (AUC INF and C max ) within 3‐fold for 81% and 86% of the tested simulations, respectively. In conclusion, the present study proposes an optimized strategy for bottom‐up PBPK model development in Simcyp Simulator. Retrospective comparison with observed clinical PK data is vital for model verification as well as further improvement in prospective predictions for future drug candidates.


  • Early-stage prediction of human intestinal metabolism from in vitro liver microsomal clearance

    by Ryan Arey, Edward Price, Louis Lin, David Stresser, Ryota Kikuchi

  • Open Access

    Endogenous plasma riboflavin is not a viable BCRP biomarker in human

    by John P. Savaryn, Ryota Kikuchi, Yuli Qian, Qin C. Ji, Gary J. Jenkins, Daniel A. J. Bow, Mohamed‐Eslam F. Mohamed

    Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co‐administration of 375 mg once daily (q.d.) cedirogant, an in vitro BCRP inhibitor, significantly increased rosuvastatin (an OATP1B1/1B3 and BCRP substrate) exposures but did not change the levels of the OATP1B endogenous biomarker coproporphyrin‐I, demonstrating that cedirogant is a clinical BCRP inhibitor. Samples from this same cedirogant clinical drug–drug interaction study were utilized to test the hypothesis that endogenous plasma riboflavin is a biomarker of BCRP inhibition. Plasma riboflavin levels in the absence of cedirogant ranged from 1 to 10 ng/mL across the 11 participants analyzed with minimal (<20%) intrasubject variability over a 24‐hour interval. Contrary to expectations, 375 mg q.d. oral administration of cedirogant did not increase riboflavin levels. These data strongly suggest that endogenous plasma riboflavin is not a viable biomarker for BCRP inhibition in humans.


  • Open Access

    Coproporphyrin‐I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug–Drug Interactions: Cedirogant Case Study

    by Ryota Kikuchi, Yuli Qian, Mohamed Badawi, John P. Savaryn, Shashikanth Gannu, Ann Eldred, Shuai Hao, Ahmed Hamed Salem, Wei Liu, Cheri E. Klein, et al.

    Cedirogant is an inverse agonist of retinoic acid‐related orphan receptor gamma thymus developed for the treatment of chronic plaque psoriasis. Cedirogant induces cytochrome P450 (CYP) 3A4 while inhibiting P‐glycoprotein (P‐gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, and OATP1B3 in vitro. Static drug–drug interactions (DDIs) predictions suggested possible clinical induction of CYP3A4, and inhibition of P‐gp, BCRP, and OATP1B1, leading to challenges in interpreting DDI studies between cedirogant and substrates of CYP3A, P‐gp, BCRP, and OATP1B1/3. Here the effects of cedirogant on the pharmacokinetics of two statin drugs were investigated in healthy participants. Coproporphyrin‐I (CP‐I), a selective endogenous OATP1B biomarker, was used to assess the impact of cedirogant on OATP1B. Cedirogant (375 mg once daily) increased rosuvastatin maximum plasma concentration (Cmax) and area under the plasma concentration curve (AUCtau) by 141% and 55%, respectively when co‐administered, whereas atorvastatin Cmax increased by 40% with no effect on its AUCtau compared with administration of rosuvastatin/atorvastatin alone. Cedirogant did not increase CP‐I exposures, indicating no clinical OATP1B inhibition. The increased rosuvastatin exposure and minimal change in atorvastatin exposure with co‐administration of cedirogant is attributed to BCRP inhibition and interplay between P‐gp/BCRP inhibition and CYP3A induction, respectively. Correlation analysis with data from two investigational drugs (glecaprevir and flubentylosin) demonstrated that OATP1B1 R‐value of > 1.5 and [Cmax,u]/[OATP1B1 IC50] of > 0.1 are associated with > 1.25‐fold increase in CP‐I Cmax ratio. This demonstrates the utility of CP‐I in disentangling mechanisms underlying a complex DDI involving multiple transporters and enzymes and proposes refined criteria for static OATP1B inhibition predictions.